Post-COVID Metabolic Changes and Diabetes Risk: A Systematic Review and Meta-Analysis

A 2024 systematic review and meta-analysis synthesized evidence from 16 studies published from 2020 onward on metabolic outcomes following COVID-19. The analysis, conducted by Bukola Lawal, suggests a 41% increased risk of new-onset diabetes among COVID-19 survivors and reports higher HbA1c and HOMA-IR levels. The findings are based on studies assessing outcomes at least three months post-recovery.

Use Cases

• Assessing the association between COVID-19 and incident diabetes based on pooled risk ratios.
• Evaluating post-infection glycemic control based on reported HbA1c and HOMA-IR standardized mean differences.
• Investigating heterogeneity in metabolic outcomes like fasting blood glucose across different study populations.
• Informing clinical guidelines for metabolic monitoring in post-COVID care based on the systematic review's conclusions.

Strengths

• Follows PRISMA guidelines for systematic review and meta-analysis methodology.
• Includes pooled quantitative results, such as a risk ratio of 1.41 (95% CI: 1.38–1.44) for new-onset diabetes.
• Reports standardized mean differences for specific metabolic markers like HbA1c (SMD 1.44) and HOMA-IR (SMD 0.96).

Limitations

• The primary risk estimate is noted to be predominantly driven by a single large-scale study, limiting generalizability.
• Substantial heterogeneity was observed across the analyzed outcomes, as reported in the results.
• The dataset is a 16.0 KB DOCX document; the underlying tabular data (rows, columns) is not directly accessible or described.

Provenance

Source

figshare

Collection Method

Systematic review and meta-analysis of observational cohort and cross-sectional studies from PubMed and Embase.

Time Range

Studies published from 2020 onward, searched on December 18, 2024.

Freshness

Last updated 2026-05-21 04:37:12; freshness should be verified.